Note: Incyte's revenues are gauged from an analysis of company filings.
Trademark applications show the products and services that Incyte is developing and marketing.
Incyte's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
Z Pharmaceutical preparations for the prevention and treatment of cancer
ZYNYZ Z Pharmaceutical preparations for the prevention and treatment of cancer
INIVIP pharmaceutical preparations for the treatment and prevention of cancer, oncological disorders, autoimmune disorders, inflammation and inflammatory disorders, hematological disorders, respiratory and infectious diseases, tissue and organ transplant rejection, dermatological disorders, connective tissue disorders, musculo-skeletal disorders, and ophthalmology disorders
Determine whether Incyte grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Incyte is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
A competitive analysis shows these companies are in the same general field as Incyte, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are in the same general field as Incyte and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.